Autophagy as a Target for Drug Development Of Skin Infection Caused by Mycobacteria.

Autor:	Bittencourt TL; Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil., da Silva Prata RB; Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil., de Andrade Silva BJ; Division of Dermatology, David Geffen School of Medicine, Los Angeles, CA, United States., de Mattos Barbosa MG; Department of Surgery, University of Michigan, Ann Arbor, MI, United States., Dalcolmo MP; Helio Fraga Reference Center, Sergio Arouca National School of Public Health, Fiocruz, Rio de Janeiro, Brazil., Pinheiro RO; Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2021 May 25; Vol. 12, pp. 674241. Date of Electronic Publication: 2021 May 25 (Print Publication: 2021).
DOI:	10.3389/fimmu.2021.674241
Abstrakt:	Pathogenic mycobacteria species may subvert the innate immune mechanisms and can modulate the activation of cells that cause disease in the skin. Cutaneous mycobacterial infection may present different clinical presentations and it is associated with stigma, deformity, and disability. The understanding of the immunopathogenic mechanisms related to mycobacterial infection in human skin is of pivotal importance to identify targets for new therapeutic strategies. The occurrence of reactional episodes and relapse in leprosy patients, the emergence of resistant mycobacteria strains, and the absence of effective drugs to treat mycobacterial cutaneous infection increased the interest in the development of therapies based on repurposed drugs against mycobacteria. The mechanism of action of many of these therapies evaluated is linked to the activation of autophagy. Autophagy is an evolutionary conserved lysosomal degradation pathway that has been associated with the control of the mycobacterial bacillary load. Here, we review the role of autophagy in the pathogenesis of cutaneous mycobacterial infection and discuss the perspectives of autophagy as a target for drug development and repurposing against cutaneous mycobacterial infection. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Bittencourt, da Silva Prata, de Andrade Silva, de Mattos Barbosa, Dalcolmo and Pinheiro.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu